Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants (Fase1B)

This study has been completed.
Centro médico Imbanaco
Asoclinic Inmunología Ltda.
Information provided by:
Malaria Vaccine and Drug Development Center Identifier:
First received: March 3, 2010
Last updated: March 5, 2010
Last verified: March 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2006
  Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)